Jpn. J. Infect. Dis., 64 (5), 439-443, 2011
To see a printable version of the article in the Adobe file format, click this [PDF] link.
Short Communication
Prompt Administration of Crimean-Congo Hemorrhagic Fever (CCHF) Virus Hyperimmunoglobulin in Patients Diagnosed with CCHF and Viral Load Monitorization by Reverse Transcriptase-PCR
Ayhan Kubar*, Mustafa Haciomeroglu1, Aykut Ozkul2, Umit Bagriacik3, Esragul Akinci4, Kenan Sener, and Hurrem Bodur4
Gulhane Military School of Medicine, Ankara; 1Refik Saydam Hygiene Center, Ankara; 2Ankara University, Ankara; 3Gazi University, Ankara; and 4Ankara Numune Training and Research Hospital, Ankara, Turkey
(Received May 10, 2011. Accepted August 9, 2011)
*Corresponding author: Mailing address: Gulhane Military School of Medicine, 06018 Ankara, Turkey. Tel: +90 312 3043414, Fax: +90 312 3043402, E-mail: このメールアドレスはスパムボットから保護されています。閲覧するにはJavaScriptを有効にする必要があります。
SUMMARY: Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the genus Nairovirus of the family Bunyaviridae, causes a severe disease in humans with high mortality rates. In Turkey, the number of patients with CCHF has increased since 2002. Here, we aimed to treat CCHF patients with CCHFV hyperimmunoglobulin. We prepared a CCHFV hyperimmunoglobulin product from 22 individuals who survived CCHF infection. A total of 26 CCHF patients were enrolled into this study. For CCHFV hyperimmunoglobulin administration, a Kubar Unit (KU) was defined. As a standard therapeutic approach, 400 KU of hyperimmunoglobulin were given to each patient as a single dose before viral load was detected. We used one-step real-time reverse transcriptase-PCR to monitor the viral load of CCHF patients. According to the one-step real-time PCR results, 15 patients with a viral load of 108 copies/mL or more were defined as high risk. In this high-risk group, the survival rate was found to be 86.6% (13/15) and 2 patients died despite CCHFV hyperimmunoglobulin administration. CCHF is a very serious and highly fatal infection, particularly for patients in the defined high-risk group. Prompt administration of CCHFV hyperimmunoglobulin might be a very promising new treatment approach, especially for high-risk individuals.